LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Lista de Ações・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

21.39 -0.37

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.06

Máximo

21.4

Indicadores-chave
By Trading Economics
Rendimento	-29M -11M
Vendas	-24M 105M
EPS	-0.09
Margem de lucro	-10.717
Funcionários	354
EBITDA	-31M -8.5M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+62.59% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-329M 2.6B
Abertura anterior	21.76
Fecho anterior	21.39

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de mai. de 2026, 23:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 de mai. de 2026, 20:53 UTC

Ganhos

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 20:33 UTC

Conversa de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 de mai. de 2026, 20:11 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 19:47 UTC

Ganhos

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 de mai. de 2026, 19:36 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 de mai. de 2026, 19:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 de mai. de 2026, 18:19 UTC

Conversa de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 de mai. de 2026, 18:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 de mai. de 2026, 18:11 UTC

Conversa de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 de mai. de 2026, 18:10 UTC

Conversa de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 de mai. de 2026, 17:55 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 17:55 UTC

Conversa de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 de mai. de 2026, 17:00 UTC

Ganhos

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de mai. de 2026, 16:02 UTC

Conversa de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 de mai. de 2026, 15:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 de mai. de 2026, 15:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 de mai. de 2026, 15:40 UTC

Conversa de Mercado

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Canada's Economy Not Looking All That Bright -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

62.59% parte superior

Previsão para 12 meses

Média 34.86 USD 62.59%

Máximo 36 USD

Mínimo 34 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.